Can Test Reports Be Reused for Overseas Registration of Home Medical Devices?

Executive Summary

Whether test reports can be reused for overseas registration of home medical devices depends on the target country's regulatory framework, the product's risk classification, differences in applicable test standards, and the qualifications of the laboratory that issued the report. Companies should first confirm whether the product falls under medical device regulation in the target country, then determine the risk class and registration pathway (e.g., EU CE MDR/IVDR, US FDA 510(k)/PMA, or GHWP member states in Southeast Asia). Existing test reports (e.g., NMPA registration tests, CE type-examination reports, or FDA listing tests) must be evaluated item by item for test standard version, test methods, sample consistency, report validity, and laboratory accreditation.

Key Summary

Reusable scenarios include safety, electromagnetic compatibility, and biocompatibility tests conducted on the same product under the same standard version. However, local specific requirements must be considered, such as Japan's PMDA requirements for local clinical data and Brazil's ANVISA mandate for Portuguese labeling and instructions. Common risks include updated test standards (e.g., the transition to IEC 60601-1 3rd edition), laboratories not recognized by the target country (e.g., OSHA NRTL in the US, EU Notified Bodies), incomplete test items (e.g., lack of cybersecurity and usability testing), and untranslated/unnotarized reports.

Companies should establish a core technical documentation package covering risk management, performance verification, clinical evaluation (or exemption justification), label and instruction draft, and quality management system certificates (ISO 13485/MDSAP), and submit through a local authorized representative. For multi-country registrations, it is advisable to first generate one test report that meets internationally recognized standards (e.g., IEC, ISO, FDA-recognized consensus standards), then supplement market-specific difference testing as required by each target country, thereby reducing repeated documentation and correction costs. Post-market maintenance, change notification, and renewal requirements should also be observed to ensure certificates remain valid.

Applicable Scenarios and Core Issues

For home medical devices such as blood pressure monitors, glucose meters, nebulizers, and massagers, companies often ask whether test reports from domestic or already approved markets can be used directly for new registrations. The answer is not simply yes or no. Reuse of test reports requires three prerequisites: the test items covered by the report are consistent with the target country's requirements; the test standard version is accepted by the target country's regulatory authority; and the laboratory that issued the report has the appropriate qualifications. For example, EN 60601-1 series test reports from EU CE certification may be partially accepted in some GHWP member states (e.g., Thailand, Malaysia), but additional local standards or language translations may be required. The core issue is that companies must first identify the target country's regulatory framework and product classification, then assess gaps in the existing evidence chain.

Home medical devices often incorporate wireless communication functions (e.g., Bluetooth, Wi-Fi), which require additional radio equipment compliance testing (e.g., ETSI in Europe, FCC in the US, TELEC in Japan). These test reports cannot be reused from medical device test reports and must be obtained independently.

Registration Decision Logic

Step 1: Confirm whether the product is a medical device in the target country

For example, the US FDA classifies home blood pressure monitors as Class II devices under 510(k), while some countries may treat them as consumer health products with more lenient oversight.

Step 2: Determine risk class and registration pathway

Under the EU MDR, home devices are often Class IIa or IIb (e.g., nebulizers). ASEAN countries generally adopt the GHWP classification framework, but specific rules differ among member states. The pathway directly influences the depth of required testing.

Step 3: Match existing test reports with applicable standard versions

For instance, IEC 60601-1-11 (home healthcare environment) is mandatory in many countries. If an old report is based on IEC 60601-1 (medical environment) without the additional home-use requirements, supplementary testing is needed.

Step 4: Verify laboratory qualifications

US FDA often requires reports from OSHA NRTL or ISO 17025-accredited laboratories that are recognized by FDA. The EU requires reports from Notified Bodies. Japan requires laboratories recognized by JMHLW or registered by the manufacturer.

Step 5: Assess clinical evaluation or exemption basis

Some home devices (e.g., electronic thermometers) may be exempt from clinical data by referencing ISO 80601 series standards, but a scientific rationale must be provided.

Step 6: Check labeling, instructions, and local agent requirements

Most countries require labels in the official local language and a designated authorized representative for post-market surveillance.

Data and Evidence

Reusable core technical documents include: product technical documentation (design principles, material list, risk management report), quality management system certificates (ISO 13485 or MDSAP), biocompatibility testing (e.g., ISO 10993 series, but confirm the referenced standard version), electrical safety and EMC testing (e.g., IEC 60601-1/1-2, noting version transitions), and performance verification reports (e.g., ISO 15197 for glucose meters).

Documents that need localization include: language-translated and notarized labels and instructions, local agent agreements, designated representative authorization, and post-market surveillance plans that comply with local regulations. For GHWP member states, if a registration from another ASEAN country (e.g., Singapore) is available, the GHWP mutual recognition framework may simplify review, but local language versions and ethics approvals (if applicable) must still be submitted.

Special attention: software-based home medical devices (e.g., health management apps) require software verification reports, cybersecurity testing, and ISO 62304 compliance declarations. These reports have low reusability because countries have significantly different regulatory requirements for standalone software (e.g., FDA SaMD, EU MDR software classification).

Common Mistakes

• Ignoring the time sensitivity of test standard versions: using outdated standard reports (e.g., IEC 60601-1 second edition) leads to corrections or retesting, extending timelines.
• Unrecognized laboratory qualifications: reports from NMPA-accredited test institutions in China may not be valid in some countries; always confirm with the target country's regulatory authority in advance.
• Ignoring product differences: when reusing test reports for the same series with different models or functions, differences are not evaluated, and partial retesting may be required.
• Neglecting home environment-specific requirements: such as usability engineering reports (IEC 62366), power consumption, and noise testing (e.g., for ventilators).
• Misjudging cost and timelines: assuming reports are fully reusable, leading to insufficient budget for supplementary testing or translation/notarization, doubling costs.

Company Preparation Checklist

• Inventory of all existing test reports (including standard version, issue date, laboratory name, and conclusions).
• Confirmation of target country product classification and registration pathway (via local agent or official guidance).
• Standard difference analysis matrix: compare target country mandatory standards with existing test standards.
• Laboratory qualification evidence (e.g., ISO 17025 certificate, NRTL, NB code, and confirmation that the lab is on the target country's recognized list).
• Technical documentation gap analysis (e.g., whether risk management covers home environment, whether usability has been assessed).
• Localized label and instruction draft (including symbol conventions, warning statements, language translation and notarization).
• Draft authorized representative agreement (clearly defining responsibilities, contract duration, and change notification obligations).
• Post-market surveillance plan (including complaint handling, adverse event reporting, annual safety reports, etc.).
• Multi-country registration schedule and budget (considering supplementary tests, certification, agent fees, and translation costs).

AIMEILI Perspective

One of the most common misjudgments is assuming that an ISO 17025 laboratory report is globally accepted. In reality, each country maintains its own list of recognized laboratories. For example, Brazil's ANVISA requires test reports from laboratories recognized by Brazil or ILAC mutual recognition agreement members; Russia's EAC requires laboratories recognized by the Customs Union. We recommend preparing a 'master test report' in the early stage, strictly following internationally accepted standards (e.g., IEC, ISO), and retaining raw data. This maximizes reusability.

Which materials can be reused? Core technical documents (design, risk, performance verification) can be used directly when the basic principles are consistent, but translation and format adjustments are needed. What must be localized? Labels and instructions, local agent agreements, and post-market surveillance systems (reporting timelines differ by country). For multi-country registration, choose a country with a mature regulatory framework (e.g., EU, US) as the 'benchmark registration.' After obtaining registration certificates and test reports, submit them to other countries to significantly reduce redundant work. Note that certificate control should be held by the local legal entity, not the foreign manufacturer; changes and renewals must be completed through the agent, otherwise registration may lapse.

Frequently Asked Questions

Do test reports have an expiry date? Can they be reused after that date?

Test reports do not have a fixed expiry date, but regulatory authorities typically require that reports be within 2 to 5 years at the time of registration review. If the report is older, confirm whether the applicable standards have been updated. For example, after the IEC 60601-1 third edition transition concluded in 2018, older versions may not be accepted. It is recommended to verify standard validity before submission.

Can NMPA registration test reports be used directly for CE or FDA applications?

No. NMPA test reports are based on domestic standards (e.g., GB 9706 series) and are issued by laboratories accredited by the Chinese NMPA. These differ from CE's EN standards or FDA-recognized consensus standards. However, they can serve as supporting technical documentation, provided you conduct a difference analysis and supplementary testing. FDA may accept data from some Chinese laboratories (e.g., Shanghai Testing Institute) if laboratory qualifications and standard equivalency are demonstrated.

For the same product registered in different countries, is it necessary to retest all items?

No. If the test standards are identical and the laboratory qualification is recognized, reports can be reused. For example, an EU CE EN 60601-1-2 (EMC) report that covers IEC CISPR 11/32 is often directly accepted by Southeast Asian countries (e.g., Indonesia, Philippines). However, countries with specific EMC limits, such as Japan and Brazil, may require additional difference testing. Evaluate item by item.

How can test reports for software-based home medical devices be reused?

Software version and cybersecurity testing are key. If the software version has not changed and testing was performed in accordance with ISO 62304, the report may be reusable. However, the US FDA requires robust cybersecurity testing (e.g., penetration testing), while the EU MDR requires ongoing updates. Assess the frequency of software updates; if the software is frequently revised, additional reports will be needed.

Continue Reading

Previous: How to prepare clinical evaluation documents for overseas registration of home medical devices?

Next: How to use ISO 13485 certificates for overseas registration of home medical devices?

Recommended reading:

• Why is the registration cycle for POCT products extended?
• What are common reasons for supplemental data requests in POCT product overseas registration?
• How to conduct post-market surveillance for POCT products?
• When is a registration change notification required for POCT products?
• What should be prepared before renewal of POCT product registration?
• How to group multiple models for POCT product registration?

Return to FAQ Center

Content Review and Applicability Boundary

Author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standard-setting bodies, and publicly available regulatory materials; industry media and project experience are used only as auxiliary references.

Applicability boundary: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements, test conclusions, or legal opinions of the target country's regulatory authority.